Recon: Genentech to Pay Immunocore $100M to Test MAGE-A4 Drug With Tecentriq

• Pharma dreads Chuck Grassley as Senate Finance chair (Axios)
• Company hiked price for opioid overdose treatment 600 percent: Senate report (The Hill) (Politico) (CBS) (Report)
• Novartis' blood disorder drug gets FDA approval for expanded use (Reuters) (Press)
• Gottlieb pushes for funding to speed gene therapy reviews (STAT)
• FDA declines to approve Aquestive's Viagra rival (Reuters) (Press)
• FDA approves new drug to treat travelers’ diarrhea (FDA)
• Playing On Fear And Fun, Hospitals Follow Pharma In Direct-To-Consumer Advertising (KHN)
• Peanut allergy treatment is effective but not always easy to tolerate, new review shows (STAT) (NYTimes) (Fierce)
• Opioid Industry Fights Efforts to Make It Pay for Crisis (WSJ)
• Cancer drug company Tesaro shares rise 39% following report that it will explore sale (CNBC) (Endpoints)
• Protesters at Sanofi in Cambridge decry high price of insulin (Boston Globe)
• Pfizer to raise US drug prices in January after previously backing down (Reuters) (CNBC)
• Alphabet unit halts glucose-detecting contact lens project (Reuters) (CNBC) (Press)
• What you're giving away with those home DNA tests (CNBC)
• Anti-vaccination stronghold in NC hit with state’s worst chickenpox outbreak in 2 decades (Washington Post)
• Maryland joins in $625 million settlement with company over adulterated cancer drugs (Baltimore Sun)

• WHO director-general: Violence in DRC is allowing Ebola to spread (STAT)
• Immunocore nabs $100M cash to co-develop preclinical asset with Roche (Endpoints) (Fierce) (PMLive)
• Pharma leaders warn Brexit deal lacks detail needed for patient safety (Financial Times)
• Pharma ignores the squabbling and prepares for a hard Brexit (Financial Times)
• Palantir to offer cancer analytics under JV deal with Germany's Merck (Reuters)
• Eli Lilly Considers Sale of China Assets to Raise Cash (Bloomberg) (Fierce)
• Novartis CEO Bets on Cutting-Edge Science to Remake Drug Giant (WSJ)
• North Korea running low on TB meds, experts fear epidemic (Washington Post)
• Is AstraZeneca looking for the ideal candidate to replace Pascal Soriot? (Endpoints) (The Times)
• NHS, Pharma and Biotech industries call on Government to protect patients in future UK-EU relationship (ABPI)
• A Chinese CAR-T company got the world’s attention with early data. At ASH, it has questions to answer (STAT)
• Roche withdraws EU Tecentriq combo application in first-line renal cell carcinoma (Pharmafile)
• NICE green light for Keytruda in melanoma setting (PharmaTimes)
• Opinion: America’s opioid crisis is a warning to the NHS. Don’t let big pharma loose on policy (The Guardian)
• The Fight Against Malaria Has Reached a Standstill (NYTimes) (Reuters)

• Pfizer, Merck KGaA's Bavencio flunks another trial, this time in ovarian cancer (Fierce) (Endpoints)
• Bristol-Myers Squibb laying off 69 employees in Florida in push to 'focus resources' (Fierce)
• Inflazome raises €40M to get NLRP3 drug into humans (Fierce) (Endpoints)
• Genfit plans US listing as NASH drugmakers race to the finish line (Endpoints)
• Seeking an edge in the global I/O race, Alphamab Oncology loads up $100M-plus from marquee backers (Endpoints)
• OTC drugmakers face an uphill battle on Amazon. But they should still be there, expert says (Fierce)
• Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst (Fierce)
• Why Is The Opioid Epidemic Still Happening? (NPR)
• Novartis Joins Call Asking FDA To Stop Biosimilar Trash-Talkers (BioCentury)
• Mundipharma name GSK veteran as new Senior Vice President & CFO (Pharmafile)
• Scientists Discover A Way To Get Drugs To The Brain Faster And More Efficiently (Forbes)

• ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting (Press)
• CStone initiates a bridging Phase I clinical trial for PD-1 antibody CS1003 with first patient dosed in China (Press)
• Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial (Press)
• DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients (Press)
• Blue Earth Diagnostics Announces Results of Investigational Phase 3 Blinded Image Evaluation Study of 18F-Fluciclovine PET Imaging in Glioma (Press)
• GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia (Press)

• Roche Diagnostics to Replace CoaguChek® XS PT Test Strips (FDA)
• Is Progress on MDR and IVDR Happening Fast Enough? (MDDI)
• FDA clears Thermi in “vaginal rejuvenation” product inquiry (MassDevice)
• Intracranial Hemorrhage Detection Software Receives FDA Clearance (MDDI)
• Edwards' Sapien 3 Ultra Valve Wins CE Mark (MDDI)
• Nico raises $13m Series B for neurosurgery devices (MassDevice)

• Florida sues drug store chains for allegedly aiding opioid crisis (The Hill)
• The SUPPORT for Patients and Communities Act (P.L. 115-271): Food and Drug Administration and Controlled Substance Provisions (CRS)
• Texas Man Convicted In $36M Drug Resale Scheme (Law360-$)
• Medtronic’s HeartWare to settle investor suit for $55m (MassDevice)
• Sunset for Cy Pres, or Standing in Cyber-Privacy Litigation – Take Your Pick (Drug & Device Law)

• FDA Advisory Committee Calendar

• Innovative skin cancer drug available on Cancer Drugs Fund (NICE)
• Reclassification of therapeutic products in dispensing category C: Evaluation concluded (Swissmedic)
• NICE publishes draft scope for new guideline on cannabis-based products for medicinal use (Pharmaceutical Journal)

• Fuji Pharma to sell Alvotech biosimilars in Japan (PharmaLetter-$)
• Innovent Biologics applies for adalimumab biosimilar in China (Biosimilar News)

• Aurobindo Pharma to launch oncology, respiratory products in US by 2021 (Economic Times)
• Superbugs kill more in India than globally, mortality rate is 13% (Times of India)
• Pharma cos to make big ticket investments as Gujarat FDCA approves layout designs of 185 drug units post GST (PharmaBiz)
• Karnataka sharply increases fees for non-statutory services for 11 certificates like GMP, CoPP & WHO-GMP (PharmaBiz)